Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. reports a 72% reduction in depression severity among patients six months after using their lead drug, MB22001, in clinical trials. The company is pioneering the use of microdoses of psychedelic medicines for take-home use, aiming to transform the treatment of depressive disorders.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
